Revumenib is used to treat acute leukemia with lysine methyltransferase 2A gene translocation (KMT2A) in patients whose disease has come back or did not respond to previous treatment. Your doctor will perform a test before you take this medicine. This medicine is available only with your doctor’s prescription. It is grouped under the following drug class(es): QTc-prolonging agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Revuforj and SNDX-5613. Its PubChem CID is 132212657.
Revumenib
| CAS No | 2169919-21-3 |
|---|---|
| Molecular Formula | C32H47FN6O4S |
| Molecular Weight | 630.8 g/mol |
| Synonyms | N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Revumenib is used to treat acute leukemia with lysine methyltransferase 2A gene translocation (KMT2A) in patients whose disease has come back or did not respond to previous treatment.
The listed CAS number is 2169919-21-3.
The listed molecular formula is C32H47FN6O4S.
The listed molecular weight is 630.8 g/mol.
N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide.
The source lists Revuforj and SNDX-5613.